Marc‐Oliver Grimm

18.1k citations
243 papers · 5.8k indexed · 2 hit papers · h-index 35

Impact in

Papers in

Marc‐Oliver Grimm

218 papers receiving 5.7k citations

Hit Papers

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial 2020 · 347 citations
34720172026202020234008001.2k

Peers

Marc‐Oliver Grimm
Comparison fields: 5 of 129
  • Oncology 2.5k
  • Pulmonary and Respiratory Medicine 2.5k
  • Urology 433
  • Surgery 2.4k
  • Cancer Research 759
Replace Jens Bedke with:
Jens Bedke Germany
Brian D. Robinson United States
Petros Grivas United States
Ajjai Alva United States
Richard Cathomas Switzerland
Aldo Bono Italy
Jörg Hennenlotter Germany
Andrea Haitel Austria
Bin S. Teh United States
Nam Hoon Cho South Korea
Marc‐Oliver Grimm relative to Jens Bedke Germany Jens Bedke's profile →
Citations per field
00.5×1.5×
Jens Bedke · 1×
Citations per year

Countries citing papers authored by Marc‐Oliver Grimm

Since Specialization
Citations

This map shows the geographic impact of Marc‐Oliver Grimm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc‐Oliver Grimm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc‐Oliver Grimm more than expected).

Fields of papers citing papers by Marc‐Oliver Grimm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc‐Oliver Grimm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc‐Oliver Grimm. The network helps show where Marc‐Oliver Grimm may publish in the future.

Co-authors

The 25 scholars most cited alongside Marc‐Oliver Grimm, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Marc‐Oliver Grimm Line = papers co-authored together Marc‐Oliver Grimm links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20260
2 20250
3 20250
4 20250
5 20250
6 20241
7 20242
8 20231
9 202312
10 202314
11 20221
12 202210
13 20227
14 202115
15 20219
16 202114
17 202130
18 20201
19 20179
20 199433

About Marc‐Oliver Grimm

Marc‐Oliver Grimm is a scholar working on Pulmonary and Respiratory Medicine, Urology, Oncology, Surgery and Cancer Research, having authored 243 papers that have together received 5.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (81 papers), Bladder and Urothelial Cancer Treatments (80 papers), Cancer Immunotherapy and Biomarkers (60 papers), Urinary and Genital Oncology Studies (35 papers), Renal and related cancers (33 papers), Prostate Cancer Treatment and Research (32 papers), Cancer Genomics and Diagnostics (23 papers) and Prostate Cancer Diagnosis and Treatment (22 papers). The work is most often cited by research in Oncology (2.5k citations), Pulmonary and Respiratory Medicine (2.5k citations), Urology (433 citations), Surgery (2.4k citations) and Cancer Research (759 citations). Marc‐Oliver Grimm has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Elizabeth R. Plimack, R. Ackermann, Manfred P. Wirth, Jens Bedke, Margitta Retz, Andrea Necchi, José Ángel Arranz, Chikara Οhyama, Sergio Bracarda and Ari David Baron. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Journal of Urology, European Urology and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026